News | May 22, 2026
OncoSil secures TGA approval for pancreatic cancer device
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Access to genomic testing, not therapy cost, is the biggest challenge
Subscribe To Our Newsletter & Stay Updated
